miRNA |
Drug Name |
CID |
NSC |
FDA |
Effect/Pattern |
Detection Method |
Level |
Phenotype |
Condition |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
High |
Ovarian Cancer |
cell line (A2780) |
hsa-let-7e |
Doxorubicin |
31703 |
NSC123127 |
approved |
resistant |
|
High |
Ovarian Cancer |
cell line (OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3, SKOV3, IOSER) |
hsa-let-7e |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
High |
Breast Cancer |
cell line (MCF-7) |
hsa-let-7e |
Verapamil |
2520 |
NSC272366 |
approved |
sensitive |
|
High |
Breast Cancer |
cell line (MCF-7) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
High |
Tongue Squamous Cell Carcinoma |
cell line (Tca8113) |
hsa-let-7e |
Fluorouracil |
3385 |
NSC19893 |
approved |
resistant |
|
High |
Colon Cancer |
cell line (DLD-1) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
High |
Ovarian Cancer |
cell line (SKOV3) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
Low |
Ovarian Cancer |
tissue and cell line (A2780) |
hsa-let-7e |
Oxaliplatin |
6857599 |
NSC266046 |
approved |
resistant |
|
High |
Colorectal Cancer |
cell line (HT-29) |
hsa-let-7e |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|
High |
Pan-Cancer |
cell line (NCI-H460, NCI-H522, NCI-H322M, HOP62, A549, EKVX, MALME-3M, NCI-H226, HT-29, HCT-116, SE-620, HCT-15, HCC2998, COLO205, HS-578T, NCI/ADR-RES, OVCAR8, OVCAR4, ACHN, SN-12C, 786-O, CAKI-1, UO-31, TK-10, A498, SK-MEL-28, UACC-257, M14, UACC-62, SK |
hsa-let-7e |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|
High |
Non-Small Cell Lung Cancer |
cell line (H1155, H358, H1993) |
hsa-let-7e |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
Low |
Gastric Cancer |
cell line (SGC7901) |
hsa-let-7e |
Vincristine |
5978 |
|
approved |
sensitive |
|
Low |
Gastric Cancer |
cell line (SGC7901) |
hsa-let-7e |
Gefitinib |
123631 |
NSC715055 |
approved |
sensitive |
|
High |
Lung Adenocarcinoma |
cell line (A549) |
hsa-let-7e |
Imatinib |
5291 |
NSC743414 |
approved |
resistant |
|
High |
Gastrointestinal Stromal Tumor |
tissue |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
High |
Esophageal Adenocarcinoma |
cell line (OE19) |
hsa-let-7e |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
Low |
Breast Cancer |
tissue and cell line (MCF-7) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
High |
Ovarian Cancer |
cell line (A2780) |
hsa-let-7e |
Plx-4720 |
24180719 |
NSC757438 |
|
resistant |
|
High |
Thyroid Cancer |
cell line (8505c, BCPAP) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
High |
Non-Small Cell Lung Cancer |
cell line (A549) |
hsa-let-7e |
Fluorouracil |
3385 |
NSC19893 |
approved |
sensitive |
|
High |
Colorectal Cancer |
cell line (DLD-1) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
Low |
Ovarian Cancer |
cell line (A2780, HO8910, ES2, CAOV3, SKOV3) |
hsa-let-7e |
Fluorouracil |
3385 |
NSC19893 |
approved |
sensitive |
|
Low |
Colorectal Cancer |
cell line (HCT-8) |
hsa-let-7e |
Daunorubicin |
30323 |
NSC82151 |
approved |
resistant |
|
High |
Acute Promyelocytic Leukemia |
cell line (HL60) |
hsa-let-7e |
Tamoxifen |
2733525 |
NSC180973 |
approved |
resistant |
|
High |
Breast Cancer |
cell line (MCF-7C) |
hsa-let-7e |
Fulvestrant |
17756771 |
NSC719276 |
approved |
resistant |
|
High |
Breast Cancer |
cell line (MCF-7) |
hsa-let-7e |
Tamoxifen |
2733525 |
NSC180973 |
approved |
resistant |
|
High |
Breast Cancer |
cell line (MCF-7) |
hsa-let-7e |
Gefitinib |
123631 |
NSC715055 |
approved |
sensitive |
|
Low |
Non-Small Cell Lung Cancer |
cell line (PC-9) |
hsa-let-7e |
Vemurafenib |
42611257 |
NSC761431 |
approved |
sensitive |
|
High |
Melanoma |
cell line (A375) |
hsa-let-7e |
Gefitinib |
123631 |
NSC715055 |
approved |
sensitive |
|
Low |
Colorectal Cancer |
cell line (HCT-116) |
hsa-let-7e |
Regorafenib |
11167602 |
NSC763932 |
approved |
sensitive |
|
Low |
Colorectal Cancer |
cell line (HCT-116) |
hsa-let-7e |
Ribavirin+Pegylated IFNa-2b |
|
|
|
resistant |
|
|
|
tissue (chronic hepatitis C) |
hsa-let-7e |
Exemestane |
60198 |
NSC713563 |
approved |
sensitive |
|
|
|
cell line (MCF-7) |
hsa-let-7e |
4-Hydroxytamoxifen+Tamoxifen |
|
|
|
resistant |
|
|
|
cell line (LY2) |
hsa-let-7e |
Ethanol+Tamoxifen |
|
|
|
resistant |
|
|
|
cell line (LY2) |
hsa-let-7e |
Methotrexate |
126941 |
NSC740 |
approved |
resistant |
|
|
|
cell line (HT29) |
hsa-let-7e |
Fluorouracil |
3385 |
NSC19893 |
approved |
resistant |
|
|
|
cell line (KM12C) (72 h) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
|
|
cell line (RPMI2650) |
hsa-let-7e |
Sunitinib |
5329102 |
NSC750690 |
approved |
resistant |
|
|
|
tissue (CardA) |
hsa-let-7e |
Paclitaxel |
36314 |
NSC125973 |
approved |
resistant |
|
|
|
cell line (SKOV3) |
hsa-let-7e |
Gemcitabine |
60750 |
NSC613327 |
approved |
resistant |
|
|
|
cell line (HuH28) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (KYSE) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (OE19) |
hsa-let-7e |
Platinum |
23939 |
|
|
resistant |
|
|
|
tissue (non-small cell lung cancer) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
|
|
cell line (A549) |
hsa-let-7e |
Ceritinib |
57379345 |
NSC776422 |
approved |
resistant |
|
|
|
cell line (H3122) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
|
|
cell line (A2780) |
hsa-let-7e |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (H460) |
hsa-let-7e |
Paclitaxel/Docetaxel/Vinorelbine/Doxorubicin/Etoposide/Methotrexate/Gemcitabine |
|
|
|
resistant |
|
|
|
cell line (Bats-72) |
hsa-let-7e-3p |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
High |
Breast Cancer |
cell line (MCF-7) |
hsa-let-7e-3p |
Verapamil |
2520 |
NSC272366 |
approved |
sensitive |
|
High |
Breast Cancer |
cell line (MCF-7) |
hsa-let-7e-3p |
Oxaliplatin |
6857599 |
NSC266046 |
approved |
resistant |
|
High |
Colorectal Cancer |
cell line (RKO) |
hsa-let-7e-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
High |
Ovarian Cancer |
tissue |
hsa-let-7e-3p |
Gefitinib |
123631 |
NSC715055 |
approved |
resistant |
|
|
|
cell line (HCC827) |
hsa-let-7e-3p |
Osimertinib |
71496458 |
NSC779217 |
approved |
resistant |
|
|
|
cell line (HCC827) |
hsa-let-7e-3p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
sensitive |
|
|
|
cell line (451Lu) |
hsa-let-7e-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (A549) |
hsa-let-7e-3p |
Tamoxifen |
2733525 |
NSC180973 |
approved |
sensitive |
|
|
|
cell line (LCC2) |
hsa-let-7e-3p |
Tamoxifen+Fulvestrant |
|
|
|
sensitive |
|
|
|
cell line (LCC9) |
hsa-let-7e-3p |
Fluorouracil |
3385 |
NSC19893 |
approved |
resistant |
|
|
|
cell line (HCT15) |
hsa-let-7e-3p |
Ethanol+Tamoxifen |
|
|
|
sensitive |
|
|
|
cell line (LY2) |
hsa-let-7e-3p |
Sunitinib |
5329102 |
NSC750690 |
approved |
sensitive |
|
|
|
tissue (CardB) |
hsa-let-7e-3p |
Pegylated interferon alpha+Ribavirin |
|
|
|
resistant |
|
|
|
tissue (chronic hepatitis C) |
hsa-let-7e-3p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (A549) |
hsa-let-7e-3p |
Ceritinib |
57379345 |
NSC776422 |
approved |
resistant |
|
|
|
cell line (H3122) |
|